Janssen-Sponsored Satellite Symposium at the 2021 SAGES Virtual Conference

## Early choices in the biologic treatment of IBD

- **SPEAKER:** Prof. Alessandro Armuzzi, MD, PhD Inflammatory Bowel Disease (IBD) Unit, Gemelli Hospital Catholic University Foundation, Rome, Italy
- DATE: Sunday, 8 August 2021
- **TIME:** 10:45 11:30
- LOCATION: SAGES Virtual Conference



Prof. Alessandro Armuzzi

Click here to register

## **LEARNING OBJECTIVES**

After this meeting, participants should be able to:

- Discuss the results of the SEAVUE trial and how these data affect early choices and treatment sequencing in IBD
- Describe recent updates in the management of UC, including safety data and on targeting IL-12/23 in UC

## **CPD** accredited

To report an adverse event, contact our pharmacovigilance department on tel: +27 (0) 11 518 7100 or email: AdverseEventZA@its.jnj.com.

Please reply to <u>NCoetzee@its.jnj.com</u> should you wish to opt-out/unsubscribe.

JANSSEN PHARMACEUTICA (PTY) LTD/(EDMS) BPK; (Reg. No./Regnr. 1980/011122/07); No 2, Medical Road, Halfway House, Midrand, 1685. www.janssen.com. Medical Info Line: 0860 11 11 17. Cert. no.: EM-63572. Date compiled: July 2021.

## Janssen TImmunology

PHARMACEUTICAL COMPANIES OF Johnson Johnson